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Abstract
Background: Platelet activating factor (PAF) has been proposed as a key factor and initial trigger in atherosclerosis.
Recently, a modulation of PAF metabolism by bioactive food constituents has been suggested. In this study we
investigated the effect of fish polar lipid consumption on PAF metabolism.
Results: The specific activities of four PAF metabolic enzymes; in leukocytes, platelets and plasma, and PAF
concentration; either in blood cells or plasma were determined. Samples were acquired at the beginning and at the
end of a previously conducted study in male New Zealand white rabbits that were fed for 45 days with atherogenic
diet supplemented (group-B, n = 6) or not (group-A, n = 6) with gilthead sea bream (Sparus aurata) polar lipids.
The specific activity of PAF-Acetylhydrolase (PAF-AH); a catabolic enzyme of PAF, was decreased in rabbits’ platelets
of both A and B groups and in rabbits’ leukocytes of group A (p < 0.05). On the other hand the specific activity of
Lipoprotein-associated Phospholipase A2 (Lp-PLA2); the catabolic enzyme of PAF in plasma was increased in both
A and B groups in both leukocytes and platelets (p < 0.05). PAF-cholinephosphotransferase (PAF-CPT); a
biosynthetic enzyme of PAF showed increased specific activity only in rabbits’ leukocytes of group A (p < 0.05).
Neither of the two groups showed any change in Lyso-PAF-acetyltransferase (Lyso-PAF-AT) specific activity (p >
0.05). Free and bound PAF levels increased in group A while decreased in group B (p < 0.05).
Conclusions: Gilthead sea bream (Sparus aurata) polar lipids modulate PAF metabolism upon atherosclerotic
conditions in rabbits leading to lower PAF levels and activity in blood of rabbits with reduced early atherosclerotic
lesions compared to control group.
Keywords: Fish polar lipids, Mediterranean Diet, Cholesterol; Platelet Activating Factor (PAF), PAF Enzymes,
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Background
Platelet Activating Factor (PAF) [1] has been proposed
as key factor in atherosclerosis development [2]. Dysre-
gulation of PAF metabolism, lead to increased PAF-
levels and triggers local inflammatory response onto the
endothelium of arteries [2] with prominent role in
atherogenesis [3,4].
The biosynthesis of PAF is accomplished through two
distinctive enzymatic pathways; the de novo pathway;
catalyzed by a specific dithiothreitol-insensitive CDP-cho-
line: 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransfer-
ase (PAF-cholinephosphotransferase; PAF-CPT, EC
2.7.8.16) that converts 1-O-alkyl-2-acetyl-glycerol to PAF
and the remodeling one; catalyzed by lyso-PAF:acetyl-CoA
acetyltransferase (Lyso-PAF-acetyltransferase; Lyso-PAF-
AT, EC 2.3.1.67) [5] which acetylates lyso-PAF. On the
other hand the catabolism of PAF in blood is catalyzed by
a PAF-specific acetylhydrolase (PAF-AH, EC 3.1.1.47)
w h o s ep l a s m af o r mi sk n o w na sLipoprotein-associated
phospholipase A2 (Lp-PLA2) [6]. PAF-AH cleaves short
chain acyl chains at the sn-2 position of phospholipids
such as, oxidized phospholipids and PAF.
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vitro the activity of PAF [5]. Many micro- and macro-
nutrients of the Mediterranean diet slow down the
development of atherosclerosis [2,7]. In previous studies
we have published that lipid minor constituents that
inhibit in vitro PAF-induced thrombosis have been iso-
lated from milk and yogurt, red and white wine and
must, seed oils, olive oil, olive pomace and fish [2].
Recently we have published that supplementation of
polar lipids from cultured gilthead sea bream (Sparus
aurata) (GSBPL) inhibit early atherosclerosis develop-
ment in diet induced hypercholesterolemic rabbits [8].
The aim of the study was to investigate how the con-
sumption of GSBPL affects the enzyme activities of PAF
metabolism and PAF levels in rabbits’ blood cells and
plasma upon atherosclerotic conditions.
Results
Isolation of fish polar lipids
Gilthead sea bream polar lipids (GSBPL) constituted the
0.23% of the whole fresh fish weight, since an amount
of 28.0 g of polar lipids were isolated from 12.0 kg of
cultured gilthead sea bream (S. aurata).
Liquid chromatographic analysis
A representative HPLC chromatographic profile of
GSBPL is illustrated in Figure 1.
Chemical determinations
The fraction of GSBPL that was eluted at 95-105 min
upon HPLC separation exerted antagonistic effect
against PAF toward washed rabbit platelets (data not
shown) and in an effort to characterize qualitatively this
fraction phosphorus and sugar determinations were per-
formed. Phosphorus determination in this fraction was
negative whereas sugar determination was positive giv-
ing 50.44 mmol of sugars per mg of fish polar lipid frac-
tion expressed as glucose.
Gas chromatographic analysis
The results of esterified fatty acids analysis in GSBPL by
gas chromatography are presented in Table 1. Quantita-
tively the most abundant fatty acids identified in GSBPL
were palmitic acid (16:0), oleic acid (18:1; cis Δ9), eico-
sapentaenoic acid (20:5; cis, cis, cis, cis, cis-Δ5,Δ8,Δ11,
Δ14,Δ17) and docosahexaenoic acid (22:6; cis, cis, cis,
cis, cis, cis-Δ4,Δ7,Δ10,Δ13,Δ16,Δ19).
PAF-basic metabolic enzyme specific activities
The PAF-metabolic specific enzyme activities of the two
experimental groups A and B at the beginning and at
the end of the experimental diet are presented in Table
2. Specific enzyme activities and PAF levels of both A
and B groups were comparable at the beginning of the
study (p > 0.05). In group A, specific activity of PAF-
CPT in leukocytes was significantly increased after 45
days on atherogenic diet compared to baseline (p <
0.05). In contrast, in group B PAF-CPT specific activity
in Leukocytes did not change compared to its initial
values. The increase of PAF-CPT specific activity in
group A resulted in higher values in group A compared
to group B at the end of the study (p < 0.05). The
Figure 1 Representative HPLC chromatograph of GSBPL. Mobile
phase was composed of solvent A; acetonitrile/methanol (60:40 v/v),
solvent B; methanol (100%) and solvent C; water (100%). The mobile
phase flow rate was adjusted to 1.0 mL/min, and UV detection
wavelength was set at 208 nm. After 55 min holding of 100%
solvent A, a linear ramp up to 100% B over 5 min was developed,
followed by a 10 min holding of 100% B, then a linear ramp up to
100% C over 5 min was followed by a 30 min holding of 100% C. A
35 min equilibration was performed before the next analysis. Elution
times of standard polar lipids were the following:
phospahtidylcholine (PC) at 50-60 min, sphingomyelin (SM) at 62-67
min, lysophospahtidylcholine (LPC) at 68-80 min and
digalactosyldiglycerides DGDG at 81-94 min.
Table 1 Gas chromatographic analysis of fatty acids in
Gilthead Sea Bream Polar Lipids (GSBPL).
Fatty acid Concentration (ppm)
14:0 17.0 ± 3.40
16:0 419 ± 83.9
a
16:1 (omega-7) 30.6 ± 6.12
18:0 99.8 ± 20.0
18:1 cis (omega-9) 155 ± 77.7
a
18:1 trans (omega-9) 29.4 ± 5.88
18:2 (omega-6) 62.1 ± 12.4
18:3 (omega-3) Traces
20:4 (omega-6) 18.8 ± 3.77
20:5 (omega-3)
b 152 ± 30.6
a
22:5 (omega-3) 26.7 ± 5.33
22:6 (omega-3)
c 405 ± 80.9
a
a: Denotes quantitatively the most abundant fatty acids identified in GSBPL;
b:
Eicosapentaenoic acid; EPA;
c: Docosahexaenoic acid; DHA).
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unlike of its activity in leukocytes, was comparable to its
initial values after 45 days. On the other hand PAF-CPT
specific activity in platelets of group B was significantly
decreased (p < 0.05), but values of PAF-CPT specific
activity of both A and B groups at the end of the study
were not statistically different.
The specific activity of Lyso-PAF-AT in leukocytes in
both A and B groups were not statistically different at the
end of the study compared to baseline. The increase of
Lyso-PAF-AT activity in leukocytes of group A failed to
reach statistical significance, but after 45 days this activity
w a sh i g h e rc o m p a r e dt ot h a to fg r o u pB( p<0 . 0 5 ) .I n
platelets of group A the specific activity of Lyso-PAF-AT
was not statistically different after 45 days, whereas in
platelets of group B, this enzyme activity was significantly
reduced (p < 0.05) but values between A and B groups at
45 days were not statistical different.
The specific activity of PAF-AH in leukocytes of group
A was significantly reduced at 45 days compared to
baseline values (p < 0.05). In contrast, PAF-AH specific
activity in leukocytes of group B was significantly
increased compared to baseline (p < 0.05). PAF-AH spe-
cific activity in platelets in both A and B groups was sig-
nificantly reduced at the end of the study (p < 0.05). In
contrast to PAF-AH in platelets, specific activity of Lp-
PLA2 in rabbits’ plasma of both A and B groups was sig-
nificantly increased (p < 0.05) after 45 days compared to
baseline.
PAF levels in rabbits’ blood
Free and bound PAF levels in both A and B groups were
comparable at the beginning of the study (p > 0.05). At
the end of the study both free and bound PAF levels
were statistically higher in group A (p < 0.05) and lower
in group B (p < 0.05) compared to the initial values,
leading to higher values in group A compared to group
B (p < 0,05) (Table 2).
Discussion
Atherosclerosis still remains a leading cause of morbid-
ity and mortality world-wide. PAF and its metabolism
Table 2 PAF metabolic enzyme specific activities in plasma, leukocytes and platelets along with PAF levels in rabbit
blood upon experimental diet.
Biochemical parameter Time (days) A (n = 6) B(n = 6)
PAF-CPT specific activity in Leukocytes
(nmol PAF/min/mg protein)
0 0.85 ± 0.29 0.57 ± 0.36
45 2.52 ± 0.81
a 0.66 ± 0.51
b
PAF-CPT specific activity in platelets
(nmol PAF/min/mg protein)
0 2.04 ± 1.11 1.49 ± 0.80
45 1.89 ± 1.30 0.49 ± 0.31
a
Lyso PAF AT specific activity in Leukocytes
(nmol PAF/min/mg protein)
0 0.0545 ± 0.0427 0.0200 ± 0.0149
45 0.1102 ± 0.0517 0.0256 ± 0.0239
b
Lyso PAF AT specific activity in platelets
(nmol PAF/min/mg protein)
0 0.0047 ± 0.0023 0.0042 ± 0.0030
45 0.0029 ± 0.0022 0.0011 ± 0.0006
a
PAFAH specific activity in Leukocytes
(nmol PAF/min/mg protein)
0 340 ± 61.3 273 ± 109
45 163 ± 15.7
a 581 ± 340
b
PAFAH specific activity in Platelets
(nmol PAF/min/mg protein)
0 96.5 ± 30.4 112 ± 20.2
45 25.0 ± 7.62
a 30.8 ± 10.7
a
Lp-PLA2 specific activity in plasma
(pmol PAF/min/μL PPP)
0 128 ± 35.3 109 ± 15.2
45 174 ± 21.6
a 239 ± 56.7
a
PAF levels in plasma; Free PAF levels
(pM)
0 3.1 ± 1.7 3.04 ± 1.23
45 5.0 ± 1.8
a 0.24 ± 0.12
a,b
PAF levels in cells; Bound PAF levels
(pM)
0 0.88 ± 0.15 1.08 ± 0.36
45 1.8 ± 0.34
a 0.18 ± 0.08
a,b
Group A followed a 1% cholesterol atherogenic diet, while group B followed the atherogenic diet supplemented with 0,06% (w/w) Gilthead Sea Bream (Sparus
aurata) Polar Lipids (GSBPL). Results are expressed as Mean Values ± Standard Deviation.
a: Denotes statistically significant difference within the same group (day
45 vs day 0; p < 0.05), according to paired t-test.
b: Denotes statistically significant difference between groups A and B (at 0 or 45 day; p < 0.05), according to
one-way ANOVA test.
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development [2-4,9]. In a research effort it has been
shown that many food-derived bioactive compounds
alter the metabolism and/or the activity of inflammatory
mediators like PAF both in in vitro and in vivo experi-
ments, contributing in a favorable clinical profile when
consumed in the diet [5].
Epidemiological and clinical trials have shown a bene-
ficial effect of fish consumption toward cardiovascular
diseases [10-12], attributed mainly to omega-3 fatty
acids [12-14]. However, recently we showed that beyond
omega-3 fatty acids, the consumption of GSBPL led to
an inhibition of early atherosclerosis development in
diet induced hypercholesterolemic rabbits [8]. In the
present study whole blood, plasma, leukocytes and plate-
lets of that previously conducted study [8] were used in
order to investigate how the consumption of GSBPL
upon atherosclrerotic conditions affect the activities of
PAF metabolic enzymes and PAF levels in rabbits. Leu-
kocytes and platelets were chosen for this study due to
their critical role in the onset of atherosclerosis
[2,15,16].
The low content of cultured gilthead sea bream
(Sparus aurata) in polar lipids (0.23% of the whole fresh
fish weight) indicates their high antiatherogenic activ-
ities since a 75% retardation of early atherosclerosis
development has been observed compared to control
group as a result of 133 mg consumption of GSBPL per
rabbit per day as noted previously [8]. Moreover, HPLC
chromatographic behavior, chemical determinations and
fatty acid analysis in GSBPL shows that the bioactive
polar lipids are peculiar glycolipids rather than classic
phospholipids with palmitic, docosahexaenoic (DHA),
oleic and eicosapentaenoic (EPA) fatty acids mainly
esterified in their structures.
In the present study leukocytes and platelets in rabbits
upon atherosclerotic conditions have been shown to
contribute to an increased PAF biosynthesis. The
increased PAF biosynthesis in group A comes from an
increased activity of PAF-CPT in leukocytes along with
a decreased activity of PAF-AH in both leucocytes and
platelets. The increased de novo biosynthesis and the
decreased catabolism of PAF in leukocytes and platelets
are in accordance with the elevated PAF levels in both
plasma (free PAF) and cells (bound PAF). These results
are paralleled with both the formation of early athero-
sclerosis lesions and the increased aggregatory response
of platelets toward PAF; expressed as reduced EC50 that
had been previously observed in group, which was not
administered with fish polar lipids [8]. These observa-
tions are in accordance with the fact that, on one hand,
elevated PAF levels can trigger platelet stimulation and
local inflammatory response onto endothelium [2,4,17],
while, on the other hand, PAF-CPT activity in
leukocytes is positively correlated with increased inflam-
mation [18].
Atherogenic diet supplemented with GSBPL in group
B has previously shown statistically significant lower
early atherosclerotic lesions compared to group A [8].
In the present study, this effect was paralleled by a mod-
ulation in PAF metabolism in leukocytes and platelets of
group B compared to that of group A. In contrast to
group A, PAF-CPT in leukocytes of group B ceases
further increase upon atherosclerotic conditions. More-
over a decrease of both PAF-CPT and Lyso PAF-AT
activities were shown in platelets of group B. As a
response of reduced PAF biosynthesis in platelets, plate-
let PAF-AH was also decreased; an observation consis-
tent with data indicating that intracellular PAF
acetylhydrolase activity is a critical component of stimu-
lated PAF production [19]. The reduced PAF levels in
both plasma and cells are in accordance with the
observed reduction of PAF biosynthetic enzymes activ-
ities in platelets and the increased activity of Lp-PLA2
in plasma. These observations are also in agreement
with the previous notion that platelets are less sensitive
to aggregation towards PAF in group administered with
fish polar lipids, where increased EC50 values were
observed [8]. The increased activity of Lp-PLA2 in
plasma of both A and B group showed a response of
this enzyme towards atherogenic conditions indepen-
dently of the GSBPL co-supplementation that cannot be
predicted only by PAF metabolism modulation in leuko-
cytes and platelets.
Conclusions
We found that GSBPL modulate PAF metabolic
enzymes upon atherosclerosis in a way that PAF levels
are maintained low. The modulation of PAF metabolic
enzyme activities leads to reduced platelet aggregatory
response toward PAF and reduced early atherosclerotic
lesions in group consumed GSBPL [8]. The appreciation
of the role of PAF and its metabolism in atherosclerosis
provides a mechanistic framework for understanding
and unravelling mechanisms where bioactive food
micronutrients are implicated in atherogenesis
prevention.
Materials and methods
Reagents
1-O-hexadecyl-2-[
3H] acetyl-sn-glycerol-3-phosphocho-
line ([
3H]-PAF) with a specific activity of 10 Ci/mmol
was obtained from New England Nuclear & Dupont
(Boston, MA, USA). 1-O-alkyl-2-sn-acetyl-glycerol
( A A G )w a sp u r c h a s e df r o mB I O M O LI n t e r n a t i o n a lL P
(Exeter, UK). Both 2,5-Diphenyloxazole (PPO) and 1,4-
bis(5-phenyl-2-oxazolyl) benzene (POPOP) were pur-
chased from BDH Chemicals (Dorset, UK). Liquid
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were purchased from Merck (Darmstadt, Germany). All
the rest analytical reagents and solvents were purchased
from Sigma (St.Louis, MO, USA).
Instruments
We performed HPLC analysis on a Hewlett-Packard ser-
ies 1100 (Avondale, PA, USA), equipped with a G1314A
HP UV spectrophotometer. A normal phase YMC-Pack
HPLC column with amino functional groups 250 × 20
mm, S-5 μm (Whatman, Maidstone, UK) was used for
the chromatographic profile of fish polar lipids, while a
cation exchange column SCX Partisil HPLC column 250
× 4.6 mm, 10 μm (Whatman (Maidstone, UK) was used
for PAF isolation.
We performed GC analysis on a Shimadzu CLASS-VP
(GC-17A) gas chromatograph (Kyoto, Japan), equipped
with a split/splitless injector, flame ionization detector
and an Agilent J&W DB-23 fused silica capillary column
60 m × 0.251 mm, 0.25 μm, (Santa Clara, CA, USA).
Homogenizations were conducted at 40KHz with a
VC50 supersonic sonicator (Newtown, CT, USA). The
liquid scintillation counter used was a 1209 Rackbeta
(Pharmacia, Wallac, Finland). PAF-induced platelet
aggregation studies were performed in a model 400 VS
aggregometer of Chrono-Log (Havertown, PA, USA)
coupled to a Chrono-Log recorder at 37°C with constant
stirring at 1200 rpm.
Isolation of fish polar lipids
Fish polar lipids were extracted from cultured gilthead
sea bream (S. aurata) cultivated in Nireus Aquaculture
S.A., situated in Chios Island, Greece. Total lipids were
extracted according to the Bligh-Dyer method [20] and
were further separated into polar and neutral lipids by
counter-current distribution [21]. GSBPL were stored at
-20°C until further analysis.
Chemical determinations in fish polar lipids
Phosphorus determination was carried out according to
the method of Bartlett [22] and sugar determination was
carried out according to the method of Galanos and
Kapoulas [23].
Fish polar lipid chromatographic profile
We acquired fish polar lipid chromatographic profile by
HPLC on an amino functional group HPLC column
using a modified previously described elution system
[24].
Gas Chromatographic analysis of fish polar lipids Fatty
acids
We prepared fatty acid methyl esters of GSBPL using a
solution 0.5N KOH in 90% aqueous CH3OH and then
we extracted them by n-hexane. The fatty acid analysis
was carried out using the internal standard method as
previously described [25].
Study design
At the beginning and after 45 days, of a previously con-
ducted study [8], we collected blood from twelve male
New Zealand white rabbits and we determined PAF-
levels and isolated leukocytes, platelets and plasma
where we determined the specific activities of the four
PAF-basic metabolic enzymes; PAF-CPT, Lyso-PAF-AT,
PAF-AH and Lp-PLA2. Animal handling and treatment
have been conducted as previously described [8]. In that
study, twelve male New Zealand white rabbits of same
weight and age were randomly divided into two groups
of six animals each and were given specific diets for 45
days. Group A was the control group and was given
typical diet supplemented with 1% cholesterol as athero-
genic diet, while Group B was given atherogenic diet
enriched with 0.06% (w/w) GSBPL. The research proto-
cols of the study have been performed with the approval
of local veterinary authorities and animal ethics
committee.
Isolation of plasma, leukocytes and platelets from blood
of rabbits
An amount of 9.0 mL of blood from hypercholesterole-
mic rabbits was obtained from each rabbit in 1.0 mL of
an anticoagulant solution of 0.085 M sodium citrate/
0.065 M citric acid, at the beginning (0 days) and at the
end (45 days) of the study where isolation of plasma,
leukocytes and platelets were performed as previously
described [26]. In each case protein was determined
according to the method of Bradford [27] with BSA as
the protein standard.
Determination of PAF-basic metabolic enzyme specific
activities
We determined PAF metabolic enzyme specific activities
in triplicate in aliquots of leukocyte and platelet homo-
genates or plasma prepared from blood of hypercholes-
terolemic rabbits taken at 0 and 45 days. PAF-CPT and
Lyso-PAF-AT specific activities were determined as pre-
viously described [26,28]. Specific enzymes activities of
PAF-CPT and Lyso-PAF-AT were expressed as nmol of
produced PAF/min/mg of sample protein present in
each assay. Specific activities of intracellular PAF-AH
and Lp-PLA2 were determined as previously described
by the TCA precipitation method [29]. We used aliquots
of 2.0 μL of plasma to determine Lp-PLA2 specific activ-
ity and aliquots of leukocytes and platelet homogenates
with a final concentration of 0.5 mg protein per mL per
assay to determine PAF-CPT, Lyso-PAF-AT and intra-
cellular PAF-AH specific activities.
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Determination of free PAF levels (PAF levels in plasma)
and bound PAF levels (PAF levels in blood cells) was
carried out in 5.0 mL of blood as previously described
[30,31].
Statistical analysis
Normality of the data was examined by the Kolmo-
gorov-Smirnov criterion before further analysis. Differ-
ences in enzyme specific activities and PAF levels within
each group and between group A and B were conducted
using the paired t-test and one way ANOVA test
respectively. Data considered being statistically signifi-
cant when p value was found below 0.05. The data were
analyzed using a statistical software package (PASW 18
for Windows, SPSS Inc., Chicago, IL, USA).
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